TipRanks
Advertisement
Advertisement

IKT Stock Latest News

Chardan biotech/pharma analysts hold analyst/industry conference call
The FlyChardan biotech/pharma analysts hold analyst/industry conference call
17h ago
IKT
GOSS
Inhibikase Therapeutics initiated with a Neutral at Chardan
PremiumThe Fly
Inhibikase Therapeutics initiated with a Neutral at Chardan
1d ago
IKT
Inhibikase advances IKT-001 in pivotal PAH Phase 3
PremiumCompany Announcements
Inhibikase advances IKT-001 in pivotal PAH Phase 3
1M ago
8K
IKT
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth
PremiumCompany Announcements
Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth
2M ago
IKT
Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)
PremiumThe Fly
Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c)
2M ago
IKT
Analyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
PremiumRatingsAnalyst Reiterates Buy on IKT, Maintaining $8 Price Target Amid Regulatory Progress and Phase 3 PAH Trial Momentum
2M ago
IKT
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
Premium
Company Announcements
Inhibikase Therapeutics Executes Pre-Funded Warrant Exchange
3M ago
8K
IKT
Inhibikase Gains FDA Orphan Drug Status for IKT-001
Premium
Company Announcements
Inhibikase Gains FDA Orphan Drug Status for IKT-001
3M ago
8K
IKT
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
PremiumThe Fly
Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA
3M ago
IKT
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
PremiumThe Fly
Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation
3M ago
IKT
Inhibikase raises $50M to fund PAH program
PremiumCompany Announcements
Inhibikase raises $50M to fund PAH program
3M ago
8K
IKT
Inhibikase Shareholders Approve Governance and Compensation Changes
PremiumCompany Announcements
Inhibikase Shareholders Approve Governance and Compensation Changes
4M ago
8K
IKT
Inhibikase Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyInhibikase Therapeutics initiated with an Outperform at Oppenheimer
4M ago
IKT
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
Premium
Ratings
Inhibikase Therapeutics: Buy Rating Reiterated on Advancing Phase 3 PAH Program and Robust IP, Price Target Maintained at $8
5M ago
IKT
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
Premium
Company Announcements
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors
5M ago
IKT
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
PremiumCompany Announcements
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension
5M ago
IKT
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
PremiumRatings
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
6M ago
IKT
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
PremiumRatings
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
6M ago
IKT
Inhibikase Begins Pivotal Phase 3 Trial in PAH
PremiumCompany Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
6M ago
8K
IKT
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
PremiumThe FlyInhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
6M ago
IKT
IKT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
IKT Upcoming Earnings Report: What to Expect?
7M ago
IKT
Inhibikase Therapeutics initiated with a Buy at Ladenburg
Premium
The Fly
Inhibikase Therapeutics initiated with a Buy at Ladenburg
7M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >